From GlobeNewswire: 2025-05-13 07:30:00

Minerva Neurosciences, Inc. reported business updates and financial results for Q1 2025, ending March 31. The company regained compliance with Nasdaq listing rules and continues on the Nasdaq Capital Market. R&D expenses decreased to $1.4 million due to FDA review costs. Net loss was $3.8 million, with $17.4 million in cash at March 31, 2025.

The company aims to treat CNS disorders with product candidates like roluperidone for schizophrenia. Minerva focuses on patient well-being and therapeutic advancements. Financially, the company had $17.4 million in cash at March 31, 2025, and reported a net loss of $3.8 million for Q1 2025. Compliance with Nasdaq listing standards was maintained.

In Q1 2025, Minerva Neurosciences saw R&D expenses decrease to $1.4 million, while G&A expenses remained at $2.5 million. Non-cash interest expenses were lower at $0 compared to $2.3 million in Q1 2024. The company’s net loss was $3.8 million, with $17.4 million in cash, cash equivalents, and restricted cash at March 31, 2025.

Minerva Neurosciences continues to focus on developing therapies for CNS disorders like schizophrenia and Parkinson’s disease. The company’s Q1 2025 financial results showed a net loss of $3.8 million, with $17.4 million in cash at March 31, 2025. Compliance with Nasdaq listing standards was maintained, allowing the company to continue trading on the Nasdaq Capital Market.



Read more at GlobeNewswire:: Minerva Neurosciences Reports First Quarter 2025 Financial